Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve th...

Full description

Bibliographic Details
Main Authors: Sara Verdura, Elisabet Cuyàs, Begoña Martin-Castillo, Javier A. Menendez
Format: Article
Language:English
Published: Taylor & Francis Group 2019-10-01
Series:OncoImmunology
Subjects:
metformin
immunotherapy
t-cells
immune checkpoints
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1633235

Internet

http://dx.doi.org/10.1080/2162402X.2019.1633235

Similar Items